NCT03548935: A reported trial by Novo Nordisk A/S
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03548935 |
|---|---|
| Title | Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 4, 2018 |
| Completion date | March 30, 2020 |
| Required reporting date | March 30, 2023, midnight |
| Actual reporting date | June 16, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |